Answers are grounded in this paper and cite their sources.
BACKGROUND: Chemoimmunotherapy is the first-line standard for advanced gastric and gastro-oesophageal junction (G/GEJ) adenocarcinoma. Whether immune-related adverse events (irAEs) mark clinical benefit, and whether any signal survives correction for immortal time bias, remains uncertain, especially for individual organ systems. METHODS: We retrospectively studied 327 patients with advanced G/GEJ adenocarcinoma receiving immune checkpoint inhibitor (ICI)-based therapy; irAEs were graded by CTCAE v5.0. Associations with overall survival (OS) and progression-free survival (PFS) were assessed with a 12-week conditional landmark analysis, time-dependent Cox models treating irAE onset as a time-varying exposure, and a cumulative organ-burden model, adjusted for baseline covariates. Objective response rate (ORR) was compared by early (≤12-week) irAE status, with estimates examined across naive, landmark and time-dependent strategies. RESULTS: irAEs occurred in 152 patients (46.5%; grade 3-4, 8.6%), most often cutaneous (20.5%) and endocrine (14.4%). In the 12-week landmark, median OS was 35.8 versus 16.0 months and median PFS 19.0 versus 9.5 months (both log-rank P<0.001). The adjusted time-dependent HR was 0.44 (95% CI 0.31-0.61) for OS and 0.43 (0.32-0.58) for PFS. Each additional organ involved lowered the OS hazard (HR 0.52, 0.40-0.67). The benefit was organ-specific: cutaneous (HR 0.30) and endocrine (0.35) irAEs were protective, whereas hepatic, gastrointestinal, musculoskeletal and pulmonary events were not. Among landmark-eligible patients, ORR was higher with early irAEs (51.0% versus 35.4%, P=0.011). The naive estimate was the most extreme, attenuating only modestly after correction. CONCLUSIONS: irAEs - particularly cutaneous and endocrine events and those accumulating across organ systems - were independently associated with longer survival after correction for immortal time bias, supporting irAE onset as a dynamic on-treatment efficacy signal that warrants prospective validation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: